Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients
机构:[1]Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[2]Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[3]Department of Breast Surgery, Chongqing Cancer Institute, Chongqing, China[4]Department of Breast and Neck Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Province, China[5]Department of Breast Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Province, China[6]Department of Breast Surgery, Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Sichuan Province, China四川省人民医院四川省肿瘤医院[7]Department of Breast Surgery, Gan Su Province Tumor Hospital, Gansu Province, China[8]Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Yunnan Province, China昆明医科大学附属第一医院[9]Department of Breast Surgery, Guizhou People's Hospital, Guizhou Province, China[10]Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi Province, China[11]Department of Breast Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Sichuan Province, China四川省人民医院[12]Department of Breast Surgery, West China Hospital of Sichuan University, Sichuan Province, China四川大学华西医院[13]Breast Surgery, The First Hospital of Kunming, Yunnan Province, China[14]Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fouth Military Medical University, Xi'an, Shaanxi Province, China[15]Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Province, China[16]Department of General Surgery, The First Affiliated Hospital of The Medical College, Shihezi University, Xinjiang Province, China[17]Department of Gastrointestinal/Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Guangxi Province, China[18]Breast Surgery, Yunnan Cancer Hospital & Third Affiliated Hospital of Kunming Medical University, Yunnan Province, China[19]Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China[20]Mammary Department, The Third People's Hospital of Shaanxi Province, China[21]Surgical Oncology, General Hospital of Ningxia Medical University, Ningxia Province, China
BACKGROUND AND PURPOSE: Breast cancer is now recognized as a clinically heterogeneous disease with a wide spectrum of epidemiological and clinicopathologic features. We aimed to evaluate whether epidemiological and clinicopathologic features are associated with the histological tumor grade of breast carcinomas in Western China. METHODS: We retrospectively collected data from the Western China Clinical Cooperation Group and assessed associations between clinicopathologic factors and histological tumor grade in 8619 female breast cancer patients. Patients were divided into two groups: Group I (tumor grade I/II) and Group II (tumor grade III). Univariable analysis and multivariable logistic regression models were used to analyze the relationships between clinicopathologic factors and tumor grade. RESULTS: Patients presenting with positive axillary lymph nodes, large tumor size (>2 cm), lymphovascular invasion, hormone receptor negativity, human epidermal growth factor receptor 2 (HER-2) positivity, and triple negativity tended to have an increased risk of a high tumor grade. However, the number of pregnancies or births was inversely correlated with the risk of a high tumor grade. In addition, patients presenting with grade III tumors were more likely to receive aggressive treatment, such as adjuvant chemotherapy, anti-HER-2 therapy, and level III axillary lymph node dissection. CONCLUSIONS: Our results suggested that several clinicopathologic factors were associated with high tumor grade of breast cancer patients in Western China.
基金:
National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China [81202090]
第一作者机构:[1]Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
通讯作者:
通讯机构:[1]Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China[2]Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China[20]Mammary Department, The Third People's Hospital of Shaanxi Province, China[21]Surgical Oncology, General Hospital of Ningxia Medical University, Ningxia Province, China[*1]Mammary Department, The Third People's Hospital of Shaanxi Province, No.309 West Yanta Road, Xi'an, 710061, Shaanxi, China[*2]Oncological Surgery, General Hospital of Ningxia Medical University Tumor Hospital, No.804 Shengli South Street, Xingqing District, Yinchuan, Ningxia, 750004, China[*3]Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China
推荐引用方式(GB/T 7714):
Zheng Ke,Tan Jin-Xiang,Li Fan,et al.Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients[J].TRANSLATIONAL ONCOLOGY.2018,11(4):1023-1033.doi:10.1016/j.tranon.2018.06.005.
APA:
Zheng, Ke,Tan, Jin-Xiang,Li, Fan,Li, Hong-Yuan,Zeng, Xiao-Hua...&Ren, Guo-Sheng.(2018).Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients.TRANSLATIONAL ONCOLOGY,11,(4)
MLA:
Zheng, Ke,et al."Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients".TRANSLATIONAL ONCOLOGY 11..4(2018):1023-1033